ZNF282

Across TCGA pan-cancer cohorts, ZNF282 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZNF282 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZNF282 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF282 expression acts as an unfavorable survival marker.

HNSC, PDAC, and CCRCC are the cancer types where ZNF282 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.664	0.890	.015	17	view →
PDAC	OS	Tertile	All	0.486	1.000	.040	2	view →
CCRCC	DFS	Median	II,III,IV	0.374	1.000	.021	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ZNF282–HNSC (DFS)

Open the HNSC breakdown →